Drug Shortage Report for EMGALITY
| Report ID | 210906 |
| Drug Identification Number | 02491087 |
| Brand name | EMGALITY |
| Common or Proper name | galcanezumab injection |
| Company Name | ELI LILLY CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | GALCANEZUMAB |
| Strength(s) | 120MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | Carton package containing one 120 mg/mL single-use prefilled pen |
| ATC code | N02CD |
| ATC description | |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | 2023-12-22 |
| Actual start date | |
| Estimated end date | 2024-02-08 |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2023-11-20 |
| Company comments | Shortage due to global manufacturing constraints and allocation. The estimated end date represents projected availability at the main Lilly warehouse. For any questions or concerns, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays). |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | EXCHANGE TOWER, 130 KING STREET WEST TORONTO, ONTARIO CANADA M5X 1B1 |
| Company contact information | Lilly Canada’s Customer Response Centre 1-888-545-5972. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2023-11-20 | French | Compare |
| v1 | 2023-11-20 | English | Compare |
Showing 1 to 2 of 2